GSK plc (GLAXF)
OTCMKTS · Delayed Price · Currency is USD
31.48
+1.13 (3.71%)
Feb 18, 2026, 2:38 PM EST
GSK plc Employees
GSK plc had 68,629 employees as of December 31, 2024. The number of employees decreased by 1,583 or -2.25% compared to the previous year.
Employees
68,629
Change (1Y)
-1,583
Growth (1Y)
-2.25%
Revenue / Employee
$640,638
Profits / Employee
$112,097
Market Cap
115.91B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| OpGen | 1 |
GSK plc News
- 1 day ago - GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade) - Seeking Alpha
- 1 day ago - GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study - GuruFocus
- 1 day ago - GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD - Seeking Alpha
- 1 day ago - GSK wins approval of Exdensur in Europe for severe asthma - Seeking Alpha
- 1 day ago - GSK Reports Promising Data for RSV Vaccine Effectiveness - GuruFocus
- 1 day ago - Europe Clears GSK's New Twice-Yearly Asthma Treatment - Benzinga
- 1 day ago - GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme - Nasdaq
- 6 days ago - Noteworthy ETF Inflows: FENI, GSK, BTI, RIO - Nasdaq